A prospectve study to evaluate the efficacy of pregabalin for chemotherapy-induced peripheral nueralgia
Phase 2
- Conditions
- Patients who suffers from peripehral neuralgia which is induced by antineaoplastic agents that were adeministered for therapy of hematological malignancies
- Registration Number
- JPRN-UMIN000005647
- Lead Sponsor
- Tokyo University, Dep. of Hematology and Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. decreased renal function (creatinine clearance equal to 60mL/min or less) 2. ocular disturbances including vision abnoramlity 3. underlying diabetes mellitus or postherpetic neuralgia 4. with previous history of pregabalin administration
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of patients whose PNQ grade (neuralgia score) improved at the 4th week after administration of pregabalin
- Secondary Outcome Measures
Name Time Method 1. The rate of patients whose PNQ grade (neuralgia score) improved at the first, second, and third week after administration of pregabalin 2. The rate of patients whose McGill Pain Questionnaire score (which depicts qualitative properties of neuralgia) changed at the first, second, and third, and 4th week after administration of pregabalin. 3. The rate of patients whose VAS score improved at the first, second, and third week after administration of pregabalin